Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean.
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2011
At a glance
- Drugs Bevacizumab; Interferon alpha; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 21 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Aug 2011 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
- 22 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.